Pegvaliase
(165-401 [IMPALA])
Trial Status Recruiting
Condition
Phenylketonuria
Phase
- Phase 4
Title
Immune Modulation During Palynziq Treatment in Adults (IMPALA)
Study Description
The overall objective of the study is to evaluate the ability of methotrexate (MTX), when co-administered with Palynziq, to suppress immune responses to Palynziq and thus improve the tolerability and efficacy of Palynziq in adults with phenylketonuria (PKU).
Primary Outcome Measures*
- To evaluate blood phenylalanine (Phe) response in adults with PKU co-administered Palynziq with MTX for 6 months
- To evaluate the ability of MTX to modulate the immune response to Palynziq in adults with PKU
Select Inclusion Criteria*
- Adults between 18 and 65 years old
- Have a confirmed diagnosis of PKU
- Are willing and medically eligible to receive Palynziq and MTX Cohort A: Have never taken Palynziq before and are willing to start it during the study Cohort B: Have blood >600 μmol/L after taking Palynziq for at least 24 weeks, are on a daily dose of at least 20 mg and unable to increase the dose further
Secondary Outcome Measures*
- To evaluate the safety of co-administration of Palynziq with MTX in adults with PKU. A treatment-emergent adverse event (TEAE) is defined as any adverse event (AE) that newly appeared, increased in frequency, or worsened in severity following initiation of the study drugs (MTX or Palynziq) administration. Incidence of TEAEs will be defined as (number of TEAEs)/(total exposure time in person-years) *100
- To characterize the pharmacokinetics (PK) of Palynziq during co-administration with MTX in adults with PKU
Select Exclusion Criteria*
- Have a serious active infection or a history of severe or recurrent infections
- Have a history of substance or alcohol abuse within the past 12 months
- Have had an organ transplant or are taking chronic immunosuppressive medications
- Are using, or plan to use, injectable PEG-containing medications other than Palynziq during the study
* Additional measures/criteria may apply.
For reference and comprehensive trial information, visit ClinicalTrials.gov NCT07477691